Lipocalin 2, the TNF-like receptor TWEAKR and its ligand TWEAK act downstream of NFAT1 to regulate breast cancer cell invasion

被引:17
作者
Gaudineau, Benoit [1 ]
Fougere, Marjorie [1 ]
Guaddachi, Frederic [1 ]
Lemoine, Frederic [2 ]
de la Grange, Pierre [2 ]
Jauliac, Sebastien [1 ]
机构
[1] Univ Paris Diderot, CNRS, UMR7212, INSERM,Inst Hematol,Hop St Louis,U944, F-75475 Paris 10, France
[2] Hop St Louis, GENOSPLICE TECHNOL, Inst Hematol, Ctr Hayem, F-75475 Paris 10, France
关键词
NFAT1; LCN2; TWEAKR; TWEAK; Motility; GELATINASE-ASSOCIATED LIPOCALIN; TRANSCRIPTION FACTOR; PANCREATIC-CANCER; EPITHELIAL-CELLS; KAPPA-B; EXPRESSION; MOTILITY; PROTEIN; TUMOR; MIGRATION;
D O I
10.1242/jcs.099879
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
NFAT1 is a transcription factor that elicits breast carcinoma cells to become invasive, thus contributing to metastasis. The molecular mechanisms by which NFAT1 operates in this respect are still poorly known. Here, we report that NFAT1 increases lipocalin 2 (LCN2) mRNA and protein expression by binding to specific sites in the LCN2 gene promoter region. We show that the LCN2 protein is required downstream of NFAT1 to increase breast cancer cell invasion. We demonstrate that the NFAT1-LCN2 axis is sufficient to regulate expression of the TNF-like receptor TWEAKR at the RNA level and of its ligand, TWEAK, at the protein level. We show, however, that TWEAKR mediates an anti-invasive effect in breast cancer cells whereas, depending on LCN2 expression, TWEAK has either anti-or pro-invasive capacities. Thus, we identify LCN2 and TWEAKR-TWEAK as crucial downstream effectors of NFAT1 that regulate breast cancer cell motility and invasive capacity.
引用
收藏
页码:4475 / 4486
页数:12
相关论文
共 59 条
  • [51] Vincent C, 2009, J BONE MINER RES, V24, P1434, DOI [10.1359/JBMR.090305, 10.1359/jbmr.090305]
  • [52] A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis
    Wiley, SR
    Cassiano, L
    Lofton, T
    Davis-Smith, T
    Winkles, JA
    Lindner, V
    Liu, H
    Daniel, TO
    Smith, CA
    Fanslow, WC
    [J]. IMMUNITY, 2001, 15 (05) : 837 - 846
  • [53] The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity
    Willis, Amanda L.
    Tran, Nhan L.
    Chatigny, Julie M.
    Charlton, Nichole
    Vu, Hong
    Brown, Sharron A. N.
    Black, Michael A.
    McDonough, Wendy S.
    Fortin, Shannon P.
    Niska, Joshua R.
    Winkles, Jeffrey A.
    Cunliffe, Heather E.
    [J]. MOLECULAR CANCER RESEARCH, 2008, 6 (05) : 725 - 734
  • [54] The TWEAK - Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting
    Winkles, Jeffrey A.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (05) : 411 - 425
  • [55] Opposing roles for calcineurin and ATF3 in squamous skin cancer
    Wu, Xunwei
    Nguyen, Bach-Cuc
    Dziunycz, Piotr
    Chang, Sungeun
    Brooks, Yang
    Lefort, Karine
    Hofbauer, Guenther F. L.
    Dotto, G. Paolo
    [J]. NATURE, 2010, 465 (7296) : 368 - U130
  • [56] An enhanced immune response in mice lacking the transcription factor NFAT1
    Xanthoudakis, S
    Viola, JPB
    Shaw, KTY
    Luo, C
    Wallace, JD
    Bozza, PT
    Curran, T
    Rao, A
    [J]. SCIENCE, 1996, 272 (5263) : 892 - 895
  • [57] Lipocalin 2 promotes breast cancer progression
    Yang, Jiang
    Bielenberg, Diane R.
    Rodig, Scott J.
    Doiron, Robert
    Clifton, Matthew C.
    Kung, Andrew L.
    Strong, Roland K.
    Zurakowski, David
    Moses, Marsha A.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (10) : 3913 - 3918
  • [58] NFAT induces breast cancer cell invasion by promoting the induction of cyclooxygenase-2
    Yiu, GK
    Toker, A
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (18) : 12210 - 12217
  • [59] Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT
    Yoeli-Lerner, M
    Yiu, GK
    Rabinovitz, I
    Erhardt, P
    Jauliac, S
    Toker, A
    [J]. MOLECULAR CELL, 2005, 20 (04) : 539 - 550